Atezolizumab for Bladder Cancer: 'Provocative' Overall Survival - Medscape

Medscape

Atezolizumab for Bladder Cancer: 'Provocative' Overall Survival Medscape CHICAGO — The anti-PD-L1 immunotherapy atezolizumab (Tecentriq, Genentech), which recently made headlines when it was approved for second-line use in bladder cancer, appears to be effective in patients with previously untreated advanced disease, ... New Immune Therapy Drug Gives Bladder Cancer Patients Fresh HopeNBCNews.com Immune-Based Drug May Help Some With Advanced Bladder CancerPhilly.com Success with immunotherapy in handling hard to treat cancerMedical Xpress PR Newswire (press release) -FiercePharma -Yahoo News -NBC Bay Area all 15 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNFQkXikOl2Z7KY-KG_rfrOHO6amlw&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779127358548&ei=7QJVV5C4MYWd3QGhi6bgAg&url=http://www.medscape.com/viewarticle/864322
via IFTTT